Catalyst Event

Moderna Inc (MRNA) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/18/2026, 12:00:00 AM

OtherSentiment: Neutral

An FDA advisory committee meeting is scheduled for 2026-06-18 to discuss the safety and effectiveness of Moderna's seasonal flu vaccine candidate (mFlusia/mRNA-1010), which is estimated to cause a ≥5% price impact scheduled.

Korean Translation

2026년 6월 18일 계절성 독감 백신 후보물질(mRNA-1010)에 대한 FDA 자문위원회 회의가 주요 규제 촉매제로서 5% 이상의 주가 영향을 줄 것으로 예정됨.

Related Recent Events

View Full Timeline